Diamyd Medical's Strategic Approach to Type 1 Diabetes
Diamyd Medical is on an exciting path to pursue accelerated approval in the U.S. for its innovative immunotherapy, Diamyd (rhGAD65/alum). This treatment is specifically designed to help maintain the body’s natural insulin production in individuals diagnosed with Stage 3 Type 1 Diabetes. To support a Biologics License Application (BLA) under the accelerated approval initiative, the company plans to utilize interim study results from its ongoing Phase 3 trial, DIAGNODE-3.
Commitment to Patients and Regulatory Engagement
Ulf Hannelius, the CEO of Diamyd Medical, underscores the company’s dedication to advancing this treatment as swiftly as possible. He stated, "We are committed to working at full speed with our partners and in close dialogue with the FDA to seize this unprecedented opportunity of making Diamyd available to patients as quickly as possible." The interim readout from the DIAGNODE-3 trial is seen as a crucial milestone, especially following a positive futility analysis that was recently completed.
Benefits of Accelerated Approval
Diamyd Medical has received Fast Track designation in the U.S. for Diamyd, with the FDA acknowledging the potential for accelerated approval if significant improvements in treatment-related C-peptide levels are demonstrated. C-peptide is an important marker of endogenous insulin production. The FDA's Accelerated Approval Program offers a pathway for quicker drug approvals for serious conditions, provided a surrogate endpoint is established.
Preparing for the Future
To facilitate the BLA submission under the FDA’s Accelerated Approval Program, Diamyd Medical is preparing to conduct an interim study readout that will include efficacy data from around 170 participants who have completed their assessment period, as well as safety data from other participants in the DIAGNODE-3 trial. The primary focus of this analysis will be on measuring C-peptide levels. The trial is designed to ensure continuous monitoring of all participants until the 24-month end-of-study evaluation is completed.
The DIAGNODE-3 Trial: An Overview
The DIAGNODE-3 trial is a significant initiative taking place across eight European countries and the United States, with a goal of enrolling approximately 330 patients by the end of 2025. This trial specifically targets recently diagnosed patients with Stage 3 Type 1 Diabetes who carry the HLA DR3-DQ2 genotype—a group known to respond favorably to Diamyd treatment in previous studies.
About Diamyd Medical
Diamyd Medical is committed to advancing precision medicine solutions aimed at preventing and treating Type 1 Diabetes as well as Latent Autoimmune Diabetes in Adults (LADA). The company’s immunotherapy, Diamyd, is an antigen-specific immunomodulatory treatment designed to help maintain the body’s natural insulin production. It has received Orphan Drug Designation and Fast Track status from the FDA for various stages of Type 1 Diabetes. Moreover, the DIAGNODE-3 trial is currently recruiting patients diagnosed with recent-onset (Stage 3) Type 1 Diabetes across eight European countries and the U.S.
Innovative Treatment Methods
Results from previous large-scale meta-analyses and a European Phase IIb trial have shown promising results when Diamyd was administered directly into a lymph node in young patients recently diagnosed with Type 1 Diabetes. This approach optimizes treatment responses, which is crucial for improving patient outcomes.
Future Developments
A biomanufacturing facility is being established in Umeå, Sweden, to produce recombinant GAD65 protein, the active ingredient in Diamyd’s immunotherapy. Additionally, Diamyd Medical is developing a GABA-based investigational drug called Remygen, aimed at addressing metabolic disorders. The company is also a significant shareholder in ventures such as NextCell Pharma AB and MainlyAI AB, reflecting its commitment to advancing medical science.
Get in Touch for More Information
If you would like to learn more about Diamyd Medical's advancements in Type 1 Diabetes treatment, please feel free to reach out directly to Ulf Hannelius, President and CEO, at +46 736 35 42 41.
Frequently Asked Questions
What is the main objective of Diamyd Medical's research?
The primary goal is to seek accelerated approval for its immunotherapy, Diamyd, to preserve insulin production in patients with Type 1 Diabetes.
How does the accelerated approval process work?
This process allows for faster approval of drugs for serious conditions based on early evidence of clinical benefits, particularly through surrogate endpoints like C-peptide levels.
What is the significance of the DIAGNODE-3 trial?
DIAGNODE-3 is pivotal as it evaluates the effectiveness of Diamyd in a specific patient population, which is crucial for supporting their BLA application.
Where is Diamyd Medical’s biomanufacturing facility located?
The facility is being developed in Umeå, Sweden, to manufacture the active ingredient in Diamyd.
Who can I contact for more information about Diamyd Medical?
For inquiries, you can contact Ulf Hannelius, President and CEO, directly by phone at +46 736 35 42 41.
